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Soluble Urokinase Plasminogen Activator Receptor Level Is an
Independent Predictor of the Presence and Severity of Coronary
Artery Disease and of Future Adverse Events
Danny J. Eapen, MD; Pankaj Manocha, MD; Nima Ghasemzadeh, MD; Riyaz S. Patel, MD; Hatem Al Kassem, MD; Muhammad Hammadah, MD;
Emir Veledar, PhD; Ngoc-Anh Le, PhD; Tomasz Pielak, BS; Christian W. Thorball, BS; Aristea Velegraki, PhD; Dimitrios T. Kremastinos, MD, PhD;
Stamatios Lerakis, MD; Laurence Sperling, MD; Arshed A. Quyyumi, MD

Introduction-—Soluble urokinase plasminogen activator receptor (suPAR) is an emerging inﬂammatory and immune biomarker.
Whether suPAR level predicts the presence and the severity of coronary artery disease (CAD), and of incident death and myocardial
infarction (MI) in subjects with suspected CAD, is unknown.
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Methods and Results-—We measured plasma suPAR levels in 3367 subjects (67% with CAD) recruited in the Emory Cardiovascular
Biobank and followed them for adverse cardiovascular (CV) outcomes of death and MI over a mean 2.11.1 years. Presence of
angiographic CAD (≥50% stenosis in ≥1 coronary artery) and its severity were quantitated using the Gensini score. Cox’s
proportional hazard survival and discrimination analyses were performed with models adjusted for established CV risk factors and
C-reactive protein levels. Elevated suPAR levels were independently associated with the presence of CAD (P<0.0001) and its
severity (P<0.0001). A plasma suPAR level ≥3.5 ng/mL (cutoff by Youden’s index) predicted future risk of MI (hazard ratio [HR]
=3.2; P<0.0001), cardiac death (HR=2.62; P<0.0001), and the combined endpoint of death and MI (HR=1.9; P<0.0001), even after
adjustment of covariates. The C-statistic for a model based on traditional risk factors was improved from 0.72 to 0.74 (P=0.008)
with the addition of suPAR.
Conclusion-—Elevated levels of plasma suPAR are associated with the presence and severity of CAD and are independent
predictors of death and MI in patients with suspected or known CAD. ( J Am Heart Assoc. 2014;3:e001118 doi: 10.1161/
JAHA.114.001118)
Key Words: biomarker • cardiovascular outcomes • coronary heart disease • C-reactive protein • inﬂammation

T

he development of atherosclerosis and subsequent
plaque rupture is a highly complex process that involves
interplay of multiple mechanistic pathways, including those
involving inﬂammation and immunity. Soluble urokinase
plasminogen activator receptor (suPAR), an emerging biomarker that represents activation of both of these pathways, has
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been implicated in atherogenesis by orchestrating cellular
adhesion, migration, and proliferation during development of
atherosclerotic plaque.1 Increased plasma and intraplaque
suPAR levels have been observed in subjects with symptomatic carotid plaques, suggesting that suPAR may be associated with the vulnerable plaque phenotype.2 Increased suPAR
levels have also been associated with incident cardiovascular
(CV) disease (CVD) in the “healthy” population, even after
adjustment for Framingham risk variables and C-reactive
protein (CRP).3,4 Moreover, in individuals presenting with STelevation myocardial infarction (STEMI), elevated suPAR level
was an independent predictor of all-cause mortality and
recurrent myocardial infarction (MI).5
Whether suPAR levels predict presence, absence, and
severity of coronary artery disease (CAD), and whether the
level is a measure of long-term risk of adverse CVD events in
subjects at risk for CAD remains unknown, and is the aim of
this study. We hypothesized that higher suPAR levels will be
associated with the presence and severity of CAD and with
incident adverse CVD events.
Journal of the American Heart Association
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Study participants were recruited as part of the Emory
Cardiology Biobank and consisted of 3763 patients enrolled
before undergoing elective or emergent cardiac catheterization across 3 Emory Healthcare sites between 2003 and
2009. Subjects with congenital heart disease, severe valvular
heart disease, severe anemia, recent blood transfusion,
myocarditis, active inﬂammatory diseases, and cancer were
not enrolled in the Biobank registry. Patients aged 20 to
90 years were interviewed to collect information on demographic characteristics, medical history, medication use, and
behavioral (lifestyle) habits. Risk-factor prevalence was
determined by physician diagnosis and/or treatment for
hypertension (HTN), hyperlipidemia, and diabetes. Smoking
was classiﬁed as nonsmoker or “ever smoked” if there was a
lifetime history of smoking at least 100 cigarettes. Blood
pressure (BP), heart rate, weight, and height were measured.
Medical records were reviewed to conﬁrm self-reported
history of MI and history of revascularization. After excluding
individuals with heart transplantation (n=170), as well as
those with missing or incomplete angiographic data or serum
and plasma samples (n=226), 3367 subjects were eligible.
The study was approved by the institutional review board at
Emory University (Atlanta, GA). All subjects provided written
informed consent at the time of enrollment.

Outcomes and Follow-up
Follow-up was conducted between 1 and 5 years for determination of the primary composite endpoint of all-cause death
and nonfatal MI, as well as the secondary endpoint of cardiac
death. This was performed by personnel blinded to the
biomarker data through telephone interview, chart review, and
linkage with the Social Security Death Index and state
records. Cause of death was adjudicated by 2 cardiologists
with a third arbitrator in case of disagreement. Cardiac death
was deﬁned as death attributable to an ischemic CV cause
(fatal MI) or sudden death resulting from an unknown, but
presumed, CV cause in high-risk patients. Medical records
were accessed or requested to validate all self-reported
events, including MI, which was again deﬁned using standard
international criteria for diagnosis of MI.6

Identiﬁcation of CAD and Severity Scoring
All coronary angiograms were scored for luminal narrowing
using a modiﬁed American Heart Association/American
College of Cardiology classiﬁcation.7 Patients were designated as having angiographically smooth normal coronary
DOI: 10.1161/JAHA.114.001118

arteries, nonsigniﬁcant CAD (visible plaque resulting in <50%
luminal stenosis), or signiﬁcant CAD (at least 1 major
epicardial vessel with ≥50% stenosis). Those with a history
of coronary artery bypass grafting (CABG) were all labeled as
having signiﬁcant CAD. The severity of their CAD was
calculated based on angiographic disease of their native
vessels before revascularization. Quantitative angiographic
scoring was performed using the Gensini score that quantiﬁes
CAD severity by a nonlinear points system for degree of
luminal narrowing. The score has prognostic signiﬁcance.8

Sample Collection
Fasting arterial blood samples for serum and plasma were
drawn at cardiac catheterization and stored at 80°C (mean,
4.9 years). Serum high-sensitivity (hs)CRP measurements
were determined using a sandwich immunoassay by FirstMark, Inc. (San Diego, CA), and plasma levels of suPAR were
measured using commercially available kits according to
the manufacturer’s instructions (suPARnostic kit; ViroGates,
Copenhagen, Denmark). Minimum detectable hsCRP and
suPAR was 0.1 mg/L and 0.1 ng/mL, respectively. Both
CRP and suPAR have previously been shown to be stable in
frozen samples.910

Statistical Analyses
Continuous variables are presented as means (SD) and
categorical variables as proportions (%). The Student t test, 1way ANOVA, and Cochran-Mantel-Haenszel’s chi-squared test
were used, as appropriate. Mann-Whitney’s U or KruskallWallis’ nonparametric tests were performed on non-normally
distributed variables. The relationship between biomarkers
and outcomes was determined using the Cox’s proportional
hazards regression in unadjusted models and in models
adjusted for established risk factors that include clinically
relevant covariates for CVD outcomes (age at baseline,
gender, race, diagnosis of HTN, diabetes, dyslipidemia, use of
statins, aspirin, clopidogrel, previous history of MI, acute MI at
presentation, estimated glomerular ﬁltration rate (eGFR),
Gensini score, hsCRP, body mass index (BMI), left ventricular
(LV) ejection fraction (LVEF), history of CABG, and smoking
status. Continuous variables were normalized by calculating
their respective z-scores ([value in individual – mean value in
the study population]/SD). Missing covariate data for the fully
adjusted model (range, 0% to 3%) was imputed and sensitivity
analysis with unimputed data found results to be similar. The
proportional hazards assumption for Cox’s models was
evaluated by plots of Schoenfeld residuals and formal testing
(a chi-square test calculated as the sum of Schoenfeld
residuals). No signiﬁcant violations of the assumption were
found.
Journal of the American Heart Association

2

ORIGINAL RESEARCH

Methods

suPAR and CAD

Eapen et al

Relationship of suPAR With Angiographic CAD
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Figure 1. ROC curve of suPAR for outcomes of All-Cause Death
and Myocardial Infarction.

suPAR levels were evaluated both as continuous (natural
log transformed) per SD and as categorical variables based
on a cutpoint determined from Youden’s index calculated
from Cox’s regression models (Figure 1). Brieﬂy, Youden’s
index is a global measure of a biomarker’s effectiveness that
calculates to the maximum difference between sensitivity and
1-speciﬁcity.11 The cutpoint for outcomes of death and MI
was determined to be 3.5 ng/mL. Analyses were performed
on all participants and in subsets of those with and those
without signiﬁcant CAD.
The ability of the standard clinical model for predicting
adverse events was calculated using the C-statistic from
Cox’s regression models before and after the addition of
suPAR.12 Using multivariate Cox’s models with the clinical
covariates noted above, continuous net reclassiﬁcation
improvement (NRI) and integrated discrimination improvement (IDI) metrics were calculated.12 Average annual risks of
events were computed by dividing observed number of events
by the observed event-speciﬁc number of person-years of
follow-up. P<0.05 from 2-sided tests were considered to
indicate statistical signiﬁcance.

Results
Baseline characteristics of the 3367 patients aged
6312 years are included in Table 1. In univariate analysis,
individuals with high suPAR levels were more likely to be
older, female, have lower low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) levels and statin dose, an
elevated hsCRP level, and a higher prevalence of diabetes,
HTN, and dyslipidemia. Management strategy (medical
DOI: 10.1161/JAHA.114.001118

suPAR levels were lowest in subjects with angiographically
normal
(“clean”)
coronary
arteries
(mean
suPAR=3.11.6 ng/mL), compared to those with either insigniﬁcant coronary atherosclerosis (<50% stenosis; mean
suPAR=3.31.9 ng/mL), or those with signiﬁcant CAD
(>50% stenosis; mean suPAR=3.51.9 ng/mL). The odds
ratio (OR) for Ln suPAR as a continuous variable for presence
of angiographic CAD compared to normal coronary arteries
was 2.1, and for presence of signiﬁcant CAD (≥50% luminal
stenosis) compared to nonsigniﬁcant (<50% luminal stenosis)
was 1.8 after adjustment for aforementioned covariates.
Similarly, the Gensini score that measures severity of CAD
was also signiﬁcantly associated with suPAR levels (Table 2).
In contrast, hsCRP was not signiﬁcantly associated with any
of these angiographic CAD indices.

Clinical and Demographic Predictors of Incident
Adverse Outcomes
Over a median follow-up period of 2.3 years, 276 patients died
(8.2%), 150 were cardiac deaths (4.9%), and 118 had an MI
(3.5%; Table 1). Using Cox’s proportional hazard models that
included all the aforementioned covariates, age (hazard ratio
[HR], 1.2; P=0.003), diabetes (HR, 1.3; P=0.01), Gensini score
(HR, 1.2; P=0.008), aspirin use (HR, 0.6; P=0.004), clopidogrel
use (HR, 1.5; P=0.002), acute MI at presentation (HR, 1.5;
P=0.009), LVEF (HR, 0.8; P<0.001), BMI (HR, 0.82; P=0.002),
and hsCRP (HR, 1.3; P<0.001) were all independent predictors
of the combined outcome of all-cause death and MI (Table 3).

Relationship Between suPAR Levels and
Outcomes
Cox’s proportional hazard regression models, adjusted for
aforementioned covariates, demonstrated that Ln suPAR had
an HR of 3.16 (P<0.0001) and the cutpoint had an HR of 1.80
for the combined outcome of all-cause death and MI (Table 4;
Figure 2A). A decrease in event-free survival was also
observed with each increase in quartile of suPAR levels
(Figure 2B). Signiﬁcant associations were observed between
Ln suPAR and the risk of cardiac death (HR=4.2; P<0.0001)
and for the combined outcomes of cardiac death and MI (HR,
2.54; P<0.001). A trend toward signiﬁcance was observed
between Ln suPAR and risk of future MI (HR, 1.6; P=0.06).
One-year risk of death and MI was 8.3% in those with an
Journal of the American Heart Association
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management, revascularization, or other) after enrollment
catheterization was not signiﬁcantly different between the
groups (Table 1).
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Table 1. Baseline Demographics and Characteristics of Entire Cohort and Cohort Divided by suPAR Cutpoint of 3.5 ng/mL
Entire Cohort (n=3367)

suPAR <3.5 ng/mL (n=2177)

suPAR ≥3.5 ng/mL (n=1190)

P Value

Age, y

6312

6111

6612

<0.0001

Male, %

64

70

54

<0.0001

Caucasian, %

83

83

83

0.826

BMI, kg/m2

306

306

307

0.219

Systolic BP, mm Hg

13723

13722

13824

0.142

Diastolic BP, mm Hg

7612

7612

7412

<0.0001

LDL, mg/dL

9938

10238

9637

<0.0001

HDL, mg/dL

4213

4213

4113

<0.0001

Glucose, mg/dL

12245

11840

13053

<0.0001

Catheterization: visually normal, %

20

23

14

<0.0001

Catheterization: >50% stenosis, %

67

64

72

<0.0001

Catheterization: Gensini score

3959

3758

4461

<0.0001
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LVEF, %

5313

5511

5114

<0.0001

eGFR, mL/min

7324

8448

6344

<0.0001

History of DM, %

32

26

45

<0.0001

History of HTN, %

92

90

95

<0.0001

History of dyslipidemia, %

70

69

71

<0.0001

Ever smoked, %

59

57

62

0.002

AMI on presentation, %

11

10

14

0.005

History of previous MI, %

31

28

36

<0.0001

On statin, %

72

74

70

0.018

On ARB or ACE-I, %

62

62

63

0.626

On aspirin, %

81

82

80

0.239

On clopidogrel, %

46

46

47

0.549

On beta-blocker, %

63

60

68

<0.0001

CRP, mg/L

7.213

5.611

1016

<0.0001

suPAR, ng/mL

3.51.9

2.50.6

5.22.3

<0.0001

Management: medical, %

57

57.7

55.6

0.253

Management: revascularization, %

41.3

40.8

42.2

0.513

Management: other, %

1.7

1.4

2.2

0.109

Follow-up: all-cause death, %

8.2

3.7

16.3

<0.0001

Follow-up: cardiac death, %

4.4

1.9

8.9

<0.0001

Follow-up: MI, %

3.5

2.8

4.7

0.004

Follow-up: revascularization, %

10.7

10.7

10.7

0.947

ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; BMI indicates body mass index; BP, blood pressure; DM, diabetes mellitus;
eGFR, estimated glomerular ﬁltration rate; HTN, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; suPAR, soluble
urokinase plasminogen activator receptor.

elevated suPAR level (≥3.5 ng/mL), compared to 2.8% in
those without an elevated level.
In the prespeciﬁed subgroups with nonsigniﬁcant CAD
(<50% stenosis; n=1044) and in those with signiﬁcant CAD
(≥50% stenosis; n=2323), suPAR levels predicted combined
outcomes of all-cause death and MI or cardiac death and MI
DOI: 10.1161/JAHA.114.001118

(Table 4). Total death/MI rates were 5.2%, 6.2%, and 12.8%
for angiographically normal, nonsigniﬁcant, and signiﬁcant
groups, respectively. We found no signiﬁcant heterogeneity in
the HR based on age, gender, race, and presence of individual
risk factors, presentation with acute MI, severity of CAD, and
eGFR values (Figure 3).
Journal of the American Heart Association
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Table 2. Association of suPAR (Natural Log Transformed and Using Cutpoint) With CAD Indices*
Angiographically Abnormal vs.
Normal OR (95% CI); P Value

Signiﬁcant CAD vs. Nonsigniﬁcant
CAD OR (95% CI); P Value

Gensini (Ln) Beta (95% CI); P Value

suPAR (Ln)

2.1 (1.61 to 2.84); <0.0001

1.79 (1.40 to 2.29); <0.0001

0.39 (0.24 to 0.54); <0.00001

suPAR ≥3.5 ng/mL

1.6 (1.29 to 2.10); <0.0001

1.37 (1.11 to 1.68); 0.003

0.19 (0.07 to 0.32); 0.03

BMI indicates body mass index; CAD, coronary artery disease; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HTN, hypertension; LVEF, left ventricular ejection fraction;
OR, odds ratio; suPAR, soluble urokinase plasminogen activator receptor.
*Adjustment for established risk factors: age, race, sex, BMI, ever smoking, HTN, diabetes, aspirin use, statin use, hyperlipidemia, eGFR, and LVEF.

In a subset of patients (N=1368) with no previous history
of CAD on enrollment (ie, excluding those with history of
acute or previous MI, percutaneous coronary intervention
[PCI], or CABG) there were 95 deaths/MI events. After
adjusting for aforementioned covariates, an elevated suPAR
level (≥3.5 ng/mL) predicts risk of future death/MI with an
HR of 2.25 (P=0.0005).
Downloaded from http://jaha.ahajournals.org/ by guest on January 29, 2018

Discrimination Testing
The C-statistic signiﬁcantly increased from 0.72 (base model
with conventional risk factors) to 0.74 (P=0.008; for Ln suPAR)
and 0.73 (P=0.04; for cutpoint) for outcomes of all-cause death
Table 3. HRs of Clinical Variables Used in Cox’s Regression
Models for Outcomes of All-Cause Death and MI
HR (95% CI)

P Value

Age

1.2 (1.1 to 1.4)

0.003

BMI

0.82 (0.7 to 0.9)

0.002

Male gender

1.2 (0.9 to 1.5)

0.175

History of diabetes

1.3 (1.1 to 1.7)

0.01

History of hypertension

0.82 (0.5 to 1.3)

0.373

History of dyslipidemia

0.9 (0.7 to 1.1)

0.28

History of CABG

0.9 (0.7 to 1.2)

0.592

History of PCI

0.9 (0.7 to 1.2)

0.669

History of smoking

1.2 (1.0 to 1.5)

0.129

Acute MI

1.5 (1.1 to 1.9)

0.009

History of previous MI

1.0 (0.8 to 1.3)

0.884

LVEF

0.8 (0.7 to 0.9)

<0.001

eGFR

1.0 (0.8 to 1.1)

0.975

Gensini score

1.2 (1.1 to 1.5)

0.008

Statin use

1.0 (0.7 to 1.3)

0.8

Clopidogrel use

1.5 (1.2 to 1.9)

0.002

Aspirin use

0.6 (0.5 to 0.9)

0.004

hsCRP (Ln)

1.3 (1.1 to 1.4)

<0.001

BMI indicates body mass index; CABG, coronary artery bypass grafting; eGFR, estimated
glomerular ﬁltration rate; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous
coronary intervention.

DOI: 10.1161/JAHA.114.001118

and MI. The signiﬁcant NRI of suPAR using the cutpoint for the
combined outcomes of all-cause death and MI corresponded to
a 6.3% rate of correctly reclassifying events and 28% rate of
correctly reclassifying nonevents, respectively (Table 5). The
relative IDI for this model was 4.1% for all-cause death and MI
(Table 5). Similar improvements were observed for the combined outcomes of cardiac death and MI and in both subgroups
with and without signiﬁcant CAD. In all groups, more nonevents
were correctly reclassiﬁed than were events.

Discussion
Herein, for the ﬁrst time, we demonstrate that elevated
plasma suPAR levels are associated with the presence and
severity of angiographic CAD. suPAR levels are higher in those
with signiﬁcant CAD compared to those with normal coronary
arteries or insigniﬁcant CAD, and greater severity of CAD is
associated with higher suPAR levels. Furthermore, we found
that suPAR is a signiﬁcant predictor of incident mortality and
morbidity in patients with suspected or established CAD, as
well as signiﬁcantly improved discrimination of future death
and MI risk over a standard clinical model, as evidenced by
improvement in the C-statistic and NRI.
Urokinase plasminogen activator (uPA) is a serine protease that, on binding its receptor, urokinase plasminogen
activator receptor (uPAR), leads to the generation of
plasmin.1 uPA is produced by vascular endothelial cells,
smooth muscle cells, monocytes, macrophages, ﬁbroblasts,
and epithelial cells.13 uPAR plays a role in development of
atherosclerosis by orchestrating cellular adhesion, migration,
and proliferation,1,14 and plasma suPAR likely reﬂects
cellular shedding of a section of uPAR from either inﬂammatory or endothelial cells. suPAR is highly stable during
storage and can be measured accurately even after repeated
cycles of freezing and thawing.15,16 Interestingly, unlike CRP,
suPAR plasma levels appear to be free of circadian changes
and are relatively stable during periods of acute stress.17
Thus, serial measurements after acute MI showed a minimal
15% average increase in suPAR levels, compared to a 365%
increase in hsCRP levels5; suPAR appears to also be superior
to hsCRP for prognostication of in-hospital mortality in
Journal of the American Heart Association
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Table 4. HRs (Natural Log Transformed [Ln], Cutpoint) for Outcomes of All-Cause Death and MI*
suPAR (Ln) HR (95% CI); P Value

suPAR ≥3.5 ng/mL HR (95% CI); P Value

Entire Cohort

3.16 (2.40 to 4.17); <0.0001

1.80 (1.38 to 2.34); <0.0001

Significant CAD

3.02 (2.14 to 4.27); <0.0001

1.52 (1.13 to 2.05); 0.006

Nonsignificant CAD

3.49 (1.93 to 6.29); <0.0001

3.18 (1.76 to 5.76); <0.0001

BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio;
HTN, hypertension; MI, myocardial infarction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; suPAR, soluble urokinase plasminogen activator receptor.
*Adjustment for established risk factors: age, race, sex, BMI, ever smoking, HTN, diabetes, aspirin use, statin use, clopidogrel use, acute MI, previous MI, PCI history, Gensini score,
hyperlipidemia, eGFR, LVEF, and CABG history.

patients with severe sepsis and septic shock.18 There are no
prospective data on interventions lowering suPAR levels;
however, subjects on long-term treatment with beta-blockers
were found to have lower levels of suPAR in their carotid
endarterectomy specimens compared to those without betablocker use.19
Downloaded from http://jaha.ahajournals.org/ by guest on January 29, 2018

A

suPAR has been extensively studied in the infectious
disease and critical care populations, but its relationship to
CVD and associated outcomes has only been recently explored.
The majority of these studies performed in Europe have
examined the relationship between suPAR and incident CVD in
healthy community-based populations.20,21 To our knowledge,
there has been only one study in 354 patients with acute STEMI
that demonstrated the prognostic utility of suPAR.5 In our
study, we show the predictive value of plasma suPAR in a much
larger population of patients with CAD and conﬁrm the ﬁndings
in those with acute MI. Interestingly, levels of suPAR were
similar in those with (11% of the cohort) and without acute MI at
presentation, and the HRs were similar for these 2 populations
(Figure 3). Moreover, HRs did not change substantially when
regression models were repeated after excluding patients

B

Figure 2. A, Kaplan Meier Survival for outcomes of All-Cause
Death and MI using suPAR cutpoint Number of events listed next
to each survival curve. B, Kaplan Meier Survival for all-cause death
or MI by quartiles of suPAR. Number of events listed next to each
survival curve. Mean suPAR levels listed next to each quartile.
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Figure 3. Forest plot interaction of suPAR with clinical covariates.
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Table 5. Net Reclassiﬁcation and Integrated Discrimination Indices for All-Cause Death and MI* Stratiﬁed by CAD Status (Ln
Transformed, Cutpoint)

NRI (%)

Events Correctly
Reclassiﬁed (%)

Nonevents Correctly
Reclassiﬁed (%)

IDI

Relative IDI (%)

suPAR (Ln)

27.4

6.0

21.4

0.0071

8.4

suPAR ≥3.5 ng/mL

34.0

6.3

28.0

0.0035

4.1

16.6

0.0052

5.9

Entire cohort

Significant CAD
suPAR (Ln)

15.4

1.1

suPAR ≥3.5 ng/mL

27.3

4.7

22.6

0.0034

3.8

suPAR (Ln)

24.0

2.1

21.9

0.0116

14.7

suPAR ≥3.5 ng/mL

22.0

25.1

0.0034

4.3

Nonsignificant CAD

3.0

Downloaded from http://jaha.ahajournals.org/ by guest on January 29, 2018

BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; HTN, hypertension; IDI,
integrated discrimination improvement; MI, myocardial infarction; LVEF, left ventricular ejection fraction; NRI, net reclassiﬁcation improvement; PCI, percutaneous coronary intervention;
suPAR, soluble urokinase plasminogen activator receptor.
*Adjustment for established risk factors: age, race, sex, BMI, ever smoking, HTN, diabetes, aspirin use, statin use, clopidogrel use, acute MI, previous MI, PCI history, Gensini score,
hyperlipidemia, eGFR, LVEF, and CABG history.

presenting with an acute MI (data not shown). Our analysis
shows that the value of suPAR in predicting future death and MI
is independent of hsCRP levels, suggesting that these biomarkers reﬂect activation of different pathophysiological pathways. Importantly, suPAR added signiﬁcantly to the statistical
model performance for prediction of all-cause death and MI by
improving the C-statistic and net reclassiﬁcation indices,
indicating that suPAR could be a valuable biomarker in risk
stratiﬁcation of patients with CAD.
Previous studies examining the role of multiple biomarkers in populations free of established CVD have demonstrated only slight improvement in predictive capacity (using
C-statistic) when added to standard clinical models.22–24
We have previously shown that a pathway-speciﬁc aggregate biomarker score comprised of hsCRP (inﬂammation),
ﬁbrin degradation products (thrombosis), and heat shock
protein 70 (cell stress) signiﬁcantly predicts cardiac death
and MI in a population with CAD.25 Whether suPAR will
add to this biomarker aggregate score requires further
investigation.
Our study has several strengths. Enrolled individuals
included women (36% of total cohort), blacks, those with
acute MI, and patients with a range of LV function, reﬂecting a
population that is typical of those undergoing cardiac
catheterization. This is different from many biomarker studies
that are conducted retrospectively on highly select populations enrolled in clinical trials. Assays were performed at one
time point by the same lab personnel, which minimized
variability. C-statistic, NRI, and IDI were calculated using
survival models that allowed for better model discrimination
and overall predictive ability. Limitations of our study include
a one-time measurement of biomarkers that may not reﬂect
DOI: 10.1161/JAHA.114.001118

levels at future time points. Our results need to be further
validated and should not be extrapolated to the general
population without suspected or known CAD. Whether moreaggressive management in individuals with elevated suPAR
levels translates to lower risk of developing CAD and
improved event-free survival remains unknown and needs
further investigation.
In conclusion, elevated suPAR levels are associated with an
increased risk of CAD and of incident adverse CVD events,
including death and MI, in the intermediate future. Whether
treatment aimed at reducing activity of suPAR can positively
alter disease course remains to be determined.
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